Review article: The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 13-19

  Weksler, B B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON; RIBAVIRIN; THROMBOPOIETIN;

BONE MARROW SUPPRESSION; CHRONIC LIVER DISEASE; CORRELATION ANALYSIS; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS C; HUMAN; HYPERSPLENISM; IMMUNOPATHOLOGY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; BLOOD PLATELETS; CHRONIC DISEASE; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; INTERFERON ALFA-2A; LIVER DISEASES; PATIENT CARE MANAGEMENT; POLYETHYLENE GLYCOLS; SPLEEN; STATISTICS AS TOPIC; THROMBOCYTOPENIA;

EID: 35448975065     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03512.x     Document Type: Review

References (42)

1. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006 23 : 1055 65.
2. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000 95 : 2936 9.
3. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001 113 : 590 5.
4. Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002 37 : 572 7.
5. Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982 4 : 451 3.
6. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 213 64.
7. Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003 326 : 111 6.
8. Aster RH. Pooling of platelets in spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966 45 : 645 57.
9. Kajiwara E, Akagi K, Azuma K, Onoyama K, Fujishima M. Evidence for an immunological pathogenesis of thrombocytopenia in chronic liver disease. Am J Gastroenterol 1995 90 : 962 6.
10. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005 100 : 1311 6.
11. Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995 50 : 173 8.
12. Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998 79 : 1106 10.
13. Sanjo A, Satoi J, Ohnishi A, Maruno J, Fukata M, Suzuki N. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 2003 18 : 638 44.
14. Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labeled platelets. Eur J Nucl Med 1993 20 : 123 9.
15. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillière's Clin Gastroenterol 2000 14 : 1009 31.
16. García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b-interferon therapy. Br J Haematol 2000 110 : 98 103.
17. Iga D, Tomimatsu M, Endo H, Ohkawa S-I, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-α therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 2005 75 : 417 23.
18. Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999 44 : 754 8.
19. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60 6.
20. Jabbour N, Zajko A, Orons P, Irish W, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998 43 : 2459 62.
21. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003 24 : 607 22.
22. Ballard HS. Hematological complications of alcoholism. Alcohol Clin Exp Res 1989 13 : 706 20.
23. Doi T, Homma H, Mezawa S, et al. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 2002 24 : 23 33.
24. Sandler SG. Review: Immune thrombocytopenic purpura: an update for immunohematologists. Immunohematology 2004 20 : 112 7.
25. Panzer S, Seel E. Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? A review Wien Med Wochenschr 2003 153 : 417 20.
26. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996 24 : 135 40.
27. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenia purpura in patients with hepatitis C virus infection. Am J Gastroenterol 2002 97 : 2040 5.
28. Pawlotsky J-M, Bouvier M, Fromont P, et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol 1995 23 : 635 9.
29. Pivetti S, Novarino A, Merico F, Tiziana Bertero M, Brunetto MR. High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. Br J Haematol 1996 95 : 204 1.
30. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005 129 : 818 24.
31. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003 325 : 135 48.
32. Gabrielli A, Manzin A, Candela M, et al. Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clin Exp Immunol 1994 97 : 87 93.
33. Cacoub P, Fabiani FL, Musset L, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994 96 : 124 32.
34. Ali A, Zein NN. Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med 2005 72 : 1005 19.
35. Kaushansky K. Thrombopoietin. N Engl J Med 1998 339 : 746 54.
36. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 2001 13 : 791 801.
37. Hodohara K, Fujii N, Yamamoto N, Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 2000 95 : 769 75.
38. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietic induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000 95 : 795 801.
39. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998 28 : 1424 9.
40. Ganser A, Carlo-Stella C, Greher J, Volkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987 70 : 1173 9.
41. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005 9 : 601 16.
42. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 32.